Volume 6.36 | Sep 15

Hematopoiesis News 6.36 September 15, 2015
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
Double Discovery Boosts Global Quest for Leukemia Cures
Researchers have discovered how a form of leukemia fights back against a ground-breaking treatment, providing vital new leads on how to outwit the deadly disease. They found that resistance develops when the cells adapt, increasing expression of proteins in the WNT/β-catenin pathway to circumvent the drug and reactivate key cancer driving genes through a previously under-recognised mechanism. [Press release from Peter MacCallum Cancer Center discussing online prepublication in Nature]
Press Release | Abstract
SmartDish™ with STEMgrid™-6 for Accurate Counting of Hematopoietic CFU Assays
PUBLICATIONS (Ranked by impact factor of the journal)
G Protein-Coupled Receptor 183 Facilitates Endothelial-to-Hematopoietic Transition via Notch1 Inhibition
Scientists showed that G protein-coupled receptor 183 signaling serves as an indispensable switch for hematopoietic stem and progenitor cell emergence by repressing Notch signaling before the onset of endothelial-to-hematopoietic transition. [Cell Res] Full Article

Overexpression and Knockout of miR-126 Both Promote Leukemogenesis through Targeting Distinct Gene Signaling
Researchers showed that both overexpression and knockout of miR-126 result in enhanced leukemogenesis in cooperation with t(8;21) fusion genes, AML1-ETO/RUNX1-RUNX1T1 or AML1-ETO9a. [Blood] Abstract

The Phosphatases STS1 and STS2 Regulate Hematopoietic Stem and Progenitor Cell Fitness
Scientists investigated the role of STS1 and STS2 on FLT3 and c-KIT phosphorylation, activity, and function in normal and stress-induced hematopoiesis. [Stem Cell Reports] Full Article | Graphical Abstract

GATA2 Regulates Wnt Signaling to Promote Primitive Red Blood Cell Fate
Investigators showed that up-regulation of canonical Wnt signaling during gastrulation blocks commitment to a hematopoietic fate while down-regulation of non-canonical Wnt signaling impairs erythroid differentiation. [Dev Biol] Abstract

FANCA Safeguards Interphase and Mitosis during Hematopoiesis In Vivo
Scientists quantified the origins of genomic instability in Fanconi anemia (FA) patients and mice in vivo and ex vivo. They found that both mitotic errors and interphase DNA damage significantly contribute to genomic instability during FA-deficient hematopoiesis and in non-hematopoietic human and murine FA primary cells. [Exp Hematol] Abstract | Full Article

Follistatin-Like 1 Attenuates Differentiation and Survival of Erythroid Cells through Smad2/3 Signaling
Scientists report that follistatin-like 1 (FSTL1) treatment impairs hemin-induced erythroid differentiation and cell survival. FSTL1 differentially regulated transforming growth factor beta and bone morphogenetic protein signaling. [Biochem Biophys Res Commun] Full Article


Efficacy and Safety of Deferasirox in Non-Thalassemic Patients with Elevated Ferritin Levels after Allogeneic Hematopoietic Stem Cell Transplantation
A multicenter DE02 trial assessed the safety, efficacy and impact of deferasirox on iron homeostasis after allogeneic hematopoietic stem cell transplantation. [Bone Marrow Transplant] Abstract

UGT2B17 Minor Histocompatibility Mismatch and Clinical Outcome after HLA-Identical Sibling Donor Stem Cell Transplantation
The authors retrospectively studied the clinical impact of a UGT2B17 mismatch in a cohort of 1127 patients receiving a hematopoietic stem cell transplantation from an HLA-identical sibling donor. [Bone Marrow Transplant] Abstract

UM171 & UM729 - Get the Authentic Small Molecules for Ex Vivo Expansion of Human HSCs
Engineering the Hematopoietic Stem Cell Niche: Frontiers in Biomaterial Science
The authors focus on development of biomaterials-based culture platforms for in vitro study of interactions between hematopoietic stem cells (HSCs) and their local microenvironment. The tools and techniques used for both examining HSC-niche interactions as well as applying these findings towards controlled HSC expansion or directed differentiation in 2D and 3D platforms are discussed. [Biotechnol J] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (Ibrutinib) for Treatment-Naive Chronic Lymphocytic Leukemia
AbbVie announced that it submitted a supplemental new drug application to the U.S. Food and Drug Administration (FDA) based on the randomized, multi-center, open-label Phase III RESONATETM-2 trial assessing the use of IMBRUVICA® (ibrutinib) versus chlorambucil in treatment-naive chronic lymphocytic leukemia patients aged 65 years or older. [AbbVie Inc.] Press Release

Avillion Announces Completion of Enrolment in Phase III BFORE Trial to Assess BOSULIF® (Bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia
Avillion LLP announced the completion of enrollment in a global Phase III clinical trial called “BFORE,” which is designed to assess the effectiveness and safety of BOSULIF® (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive chronic myelogenous leukemia. [Avillion LLP (PR Newswire Association LLC.)] Press Release

From our sponsor: Working with blood? Request your free wallchart on human blood cell frequencies.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Keystone Symposium – Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies
January 24-28, 2016
Vancouver, Canada

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Postdoctoral Position – Hematology and Immunology (University of Liege)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Director of Research – Oncology and Hematology (CancerCare Manitoba)

Postdoctoral Fellow – HMGA Chromatin Remodeling Proteins in Cancer and Stem Cell Biology (Johns Hopkins University School of Medicine)

Regulatory Coordinator – Leukemia (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Hematologic Malignancies (Northwestern University)

Postdoctoral Research Associate – Pharmacogenomics (St. Jude Children’s Research Hospital)

Postdoctoral Fellow – Hematopoietic Regeneration and Myeloid Malignancies (Weill-Cornell Medical College)

Postdoctoral Position – Hematopoietic Stem and Progenitor Cell Assays (Weill Cornell Medical School)

Research Associate – Cell Biology (Editas Medicine)

Clinical Research Coordinator – Chronic Lymphocytic Leukemia (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us